



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/893,878	06/29/2001	Robert Charles Ladner	D0617.70002US10	1764
23628	7590 06/27/2005		EXAMINER	
WOLF GREENFIELD & SACKS, PC			CELSA, BE	NNETT M
	RESERVE PLAZA TIC AVENUE		ART UNIT	PAPER NUMBER
BOSTON, M	MA 02210-2211		1639	

DATE MAILED: 06/27/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Allicant's Copy



UNITED STATES DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.

09/893,878

EXAMINER

ART UNIT PAPER

20050615

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

Notice To Comply With Sequence Rules: BONAFIDE ATTEMPT LETTER

The 4/18/05 response providing a Substitute Specification (entered) and sequence listing (entered) is acknowledged.. However, this application still fails to fully comply with the SEQUENCE RULES for the reasons recited in the attached "RAW SEQUENCE LISTING ERROR REPORT" (ATTACHED)

Since the above-mentioned reply appears to be a bona fide attempt to comply with the requirements of the sequence rules (37CFR 1.821-1.825), Applicant is given ONE MONTH from the mailing date of this communication within which to comply with the sequence rules under 37 CFR 1.821-25. Failure to comply with the sequence rules will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). Direct reply to the undersigned. Applicant is requested to return a copy of the attached NOTICE TO COMPLY with the reply.ATTACHMENT: NOTICE TO COMPLY ... SEQUENCE DISCLOSURES

Future Correspondences

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bennett Celsa whose telephone number is 571-272-0807. The examiner can normally be reached on 8-5. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Andrew Wang can be reached on 571-272-0811. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). May 5, 2005

Bennett Celsa Primary Examiner Art Unit: 1639

Art Unit: 1639

PTO-90C (Rev.04-03)

Applicant must file the items indicated below within the time period set in the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

the	requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):			
\boxtimes	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).			
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).			
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).			
\boxtimes	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."			
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).			
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).			
	7. Other: Amino acid sequences listed in claims			
	plicant Must-Provide: An initial of substitute computer readable form (CRF) copy of the "Sequence Listing".			
	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment ecifically directing its entry into the specification.			
app	A statement that the content of the paper and computer readable copies are the same and, where blicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 25(d).			
Fo	r questions regarding compliance to these requirements, please contact:			
For Rules Interpretation, call (571) 272-2510 For CRF Submission Help, call (571) 272-2501/2583. Patentin Software Program Support Technical Assistance				
	To Purchase Patentin Software703-306-2600			
DI	EASE DETIIDN A CODY OF THIS MOTICE WITH VOLID DEDLY			